106 related articles for article (PubMed ID: 31502137)
1. Multipotent Mesenchymal Stromal Cells in Patients with Chronic Myeloid Leukemia before Discontinuation of Tyrosine Kinase Inhibitors.
Petinati NA; Petrova AN; Chelysheva EY; Shukhov OA; Bykova AV; Nemchenko IS; Sats NV; Turkina AG; Drize NI
Bull Exp Biol Med; 2019 Aug; 167(4):580-583. PubMed ID: 31502137
[TBL] [Abstract][Full Text] [Related]
2. Withdrawal Syndrome After Tyrosine Kinase Inhibitor Discontinuation in Patients With Chronic Myeloid Leukemia in the Russian Prospective Study RU-SKI.
Petrova A; Chelysheva E; Shukhov O; Bykova A; Nemchenko I; Gusarova G; Tsyba N; Julhakyan H; Shuvaev V; Fominykh M; Martynkevich I; Ionova T; Turkina A
Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):267-271. PubMed ID: 32146103
[TBL] [Abstract][Full Text] [Related]
3. Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation.
Chomel JC; Bonnet ML; Sorel N; Sloma I; Bennaceur-Griscelli A; Rea D; Legros L; Marfaing-Koka A; Bourhis JH; Ame S; Guerci-Bresler A; Rousselot P; Turhan AG
Oncotarget; 2016 Jun; 7(23):35293-301. PubMed ID: 27167108
[TBL] [Abstract][Full Text] [Related]
4. Changes in Bone Marrow Stromal Progenitor Cells in Patients with Hematoblastosis at the Onset of the Disease.
Petinati NA; Shipounova IN; Fastova EA; Magomedova AU; Kravchenko SK; Chelysheva EY; Shukhov OA; Turkina AG; Sats NV; Drize NI; Parovichnikova EN; Savchenko VG
Bull Exp Biol Med; 2021 Aug; 171(4):553-558. PubMed ID: 34542753
[TBL] [Abstract][Full Text] [Related]
5. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
Saussele S; Richter J; Guilhot J; Gruber FX; Hjorth-Hansen H; Almeida A; Janssen JJWM; Mayer J; Koskenvesa P; Panayiotidis P; Olsson-Strömberg U; Martinez-Lopez J; Rousselot P; Vestergaard H; Ehrencrona H; Kairisto V; Machová Poláková K; Müller MC; Mustjoki S; Berger MG; Fabarius A; Hofmann WK; Hochhaus A; Pfirrmann M; Mahon FX;
Lancet Oncol; 2018 Jun; 19(6):747-757. PubMed ID: 29735299
[TBL] [Abstract][Full Text] [Related]
6. Increased values of the circulating PDGFβ sustains the "withdrawal syndrome" after tyrosine kinase inhibitor discontinuation in patients affected by chronic myeloid leukemia.
Galimberti S; Fontanelli G; Barsotti S; Ricci F; Guerrini F; Baratè C
Blood Cells Mol Dis; 2015 Oct; 55(3):211-2. PubMed ID: 26227847
[No Abstract] [Full Text] [Related]
7. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.
Rea D; Ame S; Berger M; Cayuela JM; Charbonnier A; Coiteux V; Cony-Makhoul P; Dubruille V; Dulucq S; Etienne G; Legros L; Nicolini F; Roche-Lestienne C; Escoffre-Barbe M; Gardembas M; Guerci-Bresler A; Johnson-Ansah H; Rigal-Huguet F; Rousselot P; Mahon FX;
Cancer; 2018 Jul; 124(14):2956-2963. PubMed ID: 29723417
[TBL] [Abstract][Full Text] [Related]
8. Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.
Legros L; Nicolini FE; Etienne G; Rousselot P; Rea D; Giraudier S; Guerci-Bresler A; Huguet F; Gardembas M; Escoffre M; Ianotto JC; Noël MP; Varet BR; Pagliardini T; Touitou I; Morisset S; Mahon FX;
Cancer; 2017 Nov; 123(22):4403-4410. PubMed ID: 28743166
[TBL] [Abstract][Full Text] [Related]
9. The spectrum of musculoskeletal symptoms in patients with chronic myeloid leukemia after stopping tyrosine kinase inhibitors.
Diab M; Schiffer CA
Leuk Res; 2019 Apr; 79():1-2. PubMed ID: 30776648
[No Abstract] [Full Text] [Related]
10. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
[TBL] [Abstract][Full Text] [Related]
11. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients.
Hernández-Boluda JC; Pereira A; Pastor-Galán I; Alvarez-Larrán A; Savchuk A; Puerta JM; Sánchez-Pina JM; Collado R; Díaz-González A; Angona A; Sagüés M; García-Gutiérrez V; Boqué C; Osorio S; Vallansot R; Palomera L; Mendizábal A; Casado LF; Pérez-Encinas M; Pérez-López R; Ferrer-Marín F; Sánchez-Guijo F; García C; Heras NL; López-Lorenzo JL; Cervantes F; Steegmann JL;
Blood Cancer J; 2018 Dec; 8(10):91. PubMed ID: 30504932
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow mesenchymal stromal cell (MSC) gene profiling in chronic myeloid leukemia (CML) patients at diagnosis and in deep molecular response induced by tyrosine kinase inhibitors (TKIs).
Aggoune D; Sorel N; Bonnet ML; Goujon JM; Tarte K; Hérault O; Domenech J; Réa D; Legros L; Johnson-Ansa H; Rousselot P; Cayssials E; Guerci-Bresler A; Bennaceur-Griscelli A; Chomel JC; Turhan AG
Leuk Res; 2017 Sep; 60():94-102. PubMed ID: 28772207
[TBL] [Abstract][Full Text] [Related]
14. The impact of introducing tyrosine kinase inhibitors on chronic myeloid leukemia survival: a population-based study.
Di Felice E; Roncaglia F; Venturelli F; Mangone L; Luminari S; Cirilli C; Carrozzi G; Giorgi Rossi P
BMC Cancer; 2018 Nov; 18(1):1069. PubMed ID: 30400842
[TBL] [Abstract][Full Text] [Related]
15. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study.
Lee SE; Choi SY; Song HY; Kim SH; Choi MY; Park JS; Kim HJ; Kim SH; Zang DY; Oh S; Kim H; Do YR; Kwak JY; Kim JA; Kim DY; Mun YC; Lee WS; Chang MH; Park J; Kwon JH; Kim DW
Haematologica; 2016 Jun; 101(6):717-23. PubMed ID: 26888022
[TBL] [Abstract][Full Text] [Related]
16. Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system.
Rashid N; Koh HA; Lin KJ; Stwalley B; Felber E
J Oncol Pharm Pract; 2018 Jun; 24(4):253-263. PubMed ID: 29284347
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of unplanned tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: retrospective analysis of real-world experience in a single institution.
Iino M; Yamamoto T; Sakamoto Y
Hematology; 2019 Dec; 24(1):355-361. PubMed ID: 30880635
[TBL] [Abstract][Full Text] [Related]
18. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
Jabbour E; Cortes J; Kantarjian H
Curr Opin Oncol; 2006 Nov; 18(6):578-83. PubMed ID: 16988578
[TBL] [Abstract][Full Text] [Related]
19. Discontinuation of tyrosine kinase inhibitors and new approaches to target leukemic stem cells: treatment-free remission as a new goal in chronic myeloid leukemia.
Breccia M; Alimena G
Cancer Lett; 2014 May; 347(1):22-8. PubMed ID: 24508029
[TBL] [Abstract][Full Text] [Related]
20. Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase.
Sasaki K; Kantarjian H; O'Brien S; Ravandi F; Konopleva M; Borthakur G; Garcia-Manero G; Wierda W; Daver N; Ferrajoli A; Takahashi K; Jain P; Rios MB; Pierce S; Jabbour E; Cortes JE
Cancer; 2018 Mar; 124(6):1160-1168. PubMed ID: 29266206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
